

Study Number:	ACCL0934
NCT #:	NCT01371656
Dataset #:	NCT01371656-D2
PMID #:	30208456

Blanks represent missing data or not applicable for analyses.  
Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Variable Number	Variable Name	Type	Label
1	USI	Character	Universal Specimen Identifier (USI)
2	TX_P	Character	Treatment (No Prophylaxis/Levofloxacin)
3	STRATUM_P	Character	Stratum
4	STRATGRPS_P	Character	Stratum (collapsed groups)
5	AGE	Numeric	Age (YRS)
6	SEX	Character	Sex
7	RACE_CAT	Character	Race
8	ETHNIC_CAT	Character	Ethnicity
9	DURGT200_A	Numeric	Days to ANC>200 uL (duration for cycle 1)
10	DURGT200_B	Numeric	Days to ANC>200 uL (duration for cycle 2)
*Note: Results presented for days to ANC>200 in Table 1 represent medians over all patient-cycles for a given stratum and treatment			
11	ANCLT500YN_SEPP_P	Character	ANC <500/uL (Never <500 / Yes <500)
12	ANCGT200POSTYN_SEPP_P	Character	ANC >200/uL Post Nadir (Never >200 / Yes >200)
13	GCSFYN	Character	Prophylactic GCSF (No/Yes)
14	CVLLOCKYN	Character	Central line lock therapy (No/Yes)
15	CHGBATHYN	Character	Chlorhexidine bathing (No/Yes)
16	CORTYN_SEPP_P	Character	Systemic Steroids
17	C1ONLY_P	Character	Only 1 cycle (Acute leukemia patients)
18	DXGRP_HSCT	Character	Diagnosis Group (HSCT patients)
19	COND_AUTO	Character	HSCT Conditioning (Autologous)
20	COND_ALLO	Character	HSCT Conditioning (Allogeneic)
21	GVHDP_ALLO	Character	GVHD Prophylaxis (Allogeneic)
22	SERO_ALLO	Character	Serotherapy (Allogeneic)
23	INEVAL	Numeric	Indicates patient is NOT evaluable for any analyses (1=Not evaluable)
24	TOTIOP_SEPP	Numeric	Total infection observation days

Study Number:	ACCL0934		
NCT #:	NCT01371656		
Dataset #:	NCT01371656-D2		
PMID #:	30208456		
Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).			
Variable Number	Variable Name	Type	Label
25	TOTBACTYN	Numeric	Total bacteremias
26	BACTYN_CR_SEPP	Numeric	Bacteria incidence (0=No/1=Yes)
27	FNYN_SEPP	Character	Fever and Neutropenia
28	TOX_INF_SEPP	Character	Severe infection
29	IFIYN_SEPP	Character	Invasive Fungal Disease
30	CDADYNG2_SEPP	Character	CDAD, diarrhea grade2+
31	CUMFEVDYS_SEPP	Numeric	Total days of fever
32	HOSPDYS_SEPP	Numeric	Days of hospitalization
33	AGTADMDYS_SEPP	Numeric	Days of antifungal therapy
34	CDADYN_SEPP	Character	CDAD positive toxin assay
35	EXP_GPA	Character	Any exposure to Gram Positive Agents
36	EXP_AMG	Character	Any exposure to Aminoglycosides Agents
37	EXP_CEPH	Character	Any exposure to Cephalosporins Agents
38	EXP_FNA	Character	Any exposure to Fever & Neutropenia Agents
39	SpecABD_GPA_TOT	Numeric	Antibiotic days by Group (Gram Positive)
40	SpecABD_AMG_TOT	Numeric	Antibiotic days by Group (Aminoglycosides)
41	SpecABD_CEPH_TOT	Numeric	Antibiotic days by Group (Cephalosporins)
42	SpecABD_FNA_TOT	Numeric	Antibiotic days by Group (Fever & Neutropenia)
43	ANY_LEVO_GAIN	Character	Any resistance developing in Levofloxacin
44	ANY_CEFE_GAIN	Character	Any resistance developing in Cefepime
45	ANY_IMI_GAIN	Character	Any resistance developing in Imipenem
46	SMITIS_PEN_GAIN	Character	Any resistance developing in Penicillin
47	SpecABD_ONLYLEVO_TOT	Numeric	Antibiotic days (Levofloxacin only)
48	ANY_GAIN	Character	Any newly detected resistance
49	INDRES	Character	Indicates patient has resistance data